Dr. Robert Lanza Receives 2006 'All Star' Award for Biotechnology.

Dr. Lanza to be honored at 11(th) Annual Mass High Tech All-Star Awards Networking Celebration

WORCESTER, Mass. -- One of the world's leading authorities on embryonic stem cells, Robert Lanza, M.D., VP, Research and Scientific Development for Advanced Cell Technology, Inc. (OTCBB: ACTC) will be honored at the 11th Annual Mass High Tech All-Star Awards Networking Reception, October 25th from 6:00-8:30pm at the Westin Boston Waterfront Hotel.

Dr. Lanza is the honoree for the category, Biotechnology; a complete listing of honorees and further details can be found at http://masshightech.bizjournals.com/masshightech/event/2544.

Robert Lanza, M.D., has over 30 years of medical research experience, and has authored/edited 18 books, including "Essentials of Stem Cell Biology" and the "Handbook of Stem Cells" (as Editor-in-Chief). Last month, Dr. Lanza served as senior author for a paper that appeared in the journal Cloning and Stem Cells, in which ACTC scientists and their collaborators rescued visual function in animals using retinal pigment epithelial cells (RPE) derived from human embryonic stem (hES) cells. In August, Dr. Lanza served as senior author of a paper in Nature, describing a method for deriving stem cells using a single-cell approach that does not harm embryos.

He is a former Fulbright Scholar, and studied as a student in the laboratory of Jonas Salk (The Salk Institute), Richard Hynes (MIT), and Nobel laureates Gerald Edelman (Rockefeller University) and Rodney Porter (Oxford University). He also worked closely (and coauthored a series of papers) with the late Harvard psychologist B.F. Skinner and heart transplant pioneer Christiaan Barnard. Dr. Lanza received his undergraduate and medical degrees from the University of Pennsylvania, where he was both a University Scholar and Benjamin Franklin Scholar.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com..

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended June 30, 2006.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.